Brief: Altamira Therapeutics Ltd Receives FDA 510(K) Clearance For Bentrio To Treat Allergic Rhinitis

Altamira Therapeutics

27/06/2022 13:50

June 27 (Reuters) - Altamira Therapeutics Ltd  CYTO.O :
    * ALTAMIRA THERAPEUTICS LTD -  ALTAMIRA THERAPEUTICS
RECEIVES FDA
510(K) CLEARANCE FOR BENTRIO TO TREAT ALLERGIC RHINITIS
    * ALTAMIRA THERAPEUTICS LTD - EXPECTS SUBSTANTIAL AND
GROWING U.S.
BENTRIO REVENUE CONTRIBUTION OVER NEXT COUPLE OF YEARS
    * ALTAMIRA THERAPEUTICS -  RECENTLY ESTABLISHED OTC CONSUMER
HEALTH BUSINESS UNIT EXPECTS TO MAKE PRODUCT AVAILABLE IN U.S.
LATER IN Q3

Further company coverage:  CYTO.O